冠状动脉介入治疗靶血管并发症及其处理
|
摘要
在冠状动脉介入治疗过程中,不可避免的出现相关血管并发症,本文将冠状动脉介入治疗过程中常见的靶血管并发症加以阐述分别从冠脉夹层、急性冠状动脉闭塞、冠状动脉无复流、冠状动脉穿孔、支架内血栓、支架脱载及其他7个方面阐述靶血管并发症原因分类处理及预防,旨在减少手术并发症的发生。
引文
[1]侯传龙,王世喜,李鹤.FFR在急性ST抬高型心肌梗死在择期处理非罪犯血管中的应用价值[J].中外医疗,2017,36(7):58-59,62.
[2]于士祥,高山.冠心病介入治疗中常见并发症的相关探讨[J].医学理论与实践,2017,30(17):2547-2548.
[3]尚瑞平.Guidezilla延长导管联合球囊锚定技术在重度迂曲冠脉中的应用[J].中国保健营养,2017,27(19):119.
[4]刘洋,刘恒亮,耿国英,等.急诊PCI冠状动脉内注射替罗非班用于糖尿病伴STEMI患者效果观察[J].山东医药,2016,56(20):75-77.
[5]田翠燕,韩琼,陈树涛,等.直接经皮腔内冠状动脉介入治疗术前应用替罗非班对ST段抬高型心肌梗死患者无/慢复流的影响[J].临床荟萃,2016,37(7):748-752.
[6]李永忠,杨宝平,于妍,等.急诊PCI术中无复流应用血栓抽吸导管装置对远端血管抽吸处理的临床疗效[J].临床荟萃,2016,31(11):1188-1191.
[7]李靖.冠状动脉介入治疗并发症及预防[J].世界最新医学信息文摘(连续型电子期刊),2016,16(53):38,45.
[8]马弋力,李屏,廖付军.经皮冠脉介入治疗的并发症及处理研究进展[J].中西医结合心血管病电子杂志,2016,4(19):29-30.
[9]陈翔,朱嘉琦,郑兴.Glubran-2胶栓塞治疗冠状动脉穿孔[J].国际心血管病杂志,2016,43(5):313-314.
[10]马弋力,李屏,廖付军.经皮冠脉介入治疗的并发症及处理研究进展[J].中西医结合心血管病电子杂志,2016,4(19):29-30.
[11]Singh V,Badheka AO,Arora S,et al.Comparison of inhospital mortality,length of hospitalization,costs,and vascular complications of percutaneous coronary interventions guidedby ultrasound versus angiography[J].Am J Cardiol,2015,115(10):1357-1366.
[12]Jhagroe DA,Janssen Pw,Ten Berg JM.Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting[J].Curr Opin Cardiol,2015,30(4):319-324.
[13]Badheka AO,Patel NJ,Grover P,et al.Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes:a 5-year United States experience(2005-2009)[J].Circulation,2014,130(16):1392-1406.
[14]Peterson ED,Dai D,De Long ER,et al.Contemporary mortality risk prediction for percutaneous coronary intervention:results from588 398 procedures in the National Cardiovascular Data Registry[J].J Am Coll Cardiol,2010,55(18):1923-1932.
[15]Jolly SS,Amlani S,Hamon M,et al.Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events:a systematic review and meta-analysis of randomized trials[J].Am Heart J,2009,157(1):132-140.
[16]Nikolsky E,Mehran R,Halkin A,et al.Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures:a meta-analysis[J].J Am Coll Cardiol,2004,44(6):1200-1209.
[17]Aggarwal A,Dai D,Rumsfeld JS,et al.Incidence and predictors of stroke associated with percutaneous coronary intervention[J].Am J Cardiol,2009,104(3):349-353.
[18]Dukkipati S,O'Neill WW,Harjai KJ,et al.Characteristics of cerebrovascular accidents after percutaneous coronary interventions[J].J Am Coll Cardiol,2004,43(7):1161-1167.
[19]金琴花,盖鲁粤,杨庭树,等.冠心病介入治疗1 501例并发症分析—单中心16年资料[J].中国介入心脏病学杂志,2004,12(6):326-329.
[20]Mueller C,Buerkle G,Buettner HJ,et al.Prevention of contrast media-associated nephropathy:randomized comparison of 2 hydration regimens in 1 620 patients undergoing coronary angioplasty[J].Arch Intern Med,2002,162(3):329-336.
[21]Solomon R,Werner C,Mann D,et al.Effects of saline,mannitol,and furosemide to prevent acute decreases in renal function induced by radiocontrast agents[J].N Engl J Med,1994,331(21):1416-1420.
[2]于士祥,高山.冠心病介入治疗中常见并发症的相关探讨[J].医学理论与实践,2017,30(17):2547-2548.
[3]尚瑞平.Guidezilla延长导管联合球囊锚定技术在重度迂曲冠脉中的应用[J].中国保健营养,2017,27(19):119.
[4]刘洋,刘恒亮,耿国英,等.急诊PCI冠状动脉内注射替罗非班用于糖尿病伴STEMI患者效果观察[J].山东医药,2016,56(20):75-77.
[5]田翠燕,韩琼,陈树涛,等.直接经皮腔内冠状动脉介入治疗术前应用替罗非班对ST段抬高型心肌梗死患者无/慢复流的影响[J].临床荟萃,2016,37(7):748-752.
[6]李永忠,杨宝平,于妍,等.急诊PCI术中无复流应用血栓抽吸导管装置对远端血管抽吸处理的临床疗效[J].临床荟萃,2016,31(11):1188-1191.
[7]李靖.冠状动脉介入治疗并发症及预防[J].世界最新医学信息文摘(连续型电子期刊),2016,16(53):38,45.
[8]马弋力,李屏,廖付军.经皮冠脉介入治疗的并发症及处理研究进展[J].中西医结合心血管病电子杂志,2016,4(19):29-30.
[9]陈翔,朱嘉琦,郑兴.Glubran-2胶栓塞治疗冠状动脉穿孔[J].国际心血管病杂志,2016,43(5):313-314.
[10]马弋力,李屏,廖付军.经皮冠脉介入治疗的并发症及处理研究进展[J].中西医结合心血管病电子杂志,2016,4(19):29-30.
[11]Singh V,Badheka AO,Arora S,et al.Comparison of inhospital mortality,length of hospitalization,costs,and vascular complications of percutaneous coronary interventions guidedby ultrasound versus angiography[J].Am J Cardiol,2015,115(10):1357-1366.
[12]Jhagroe DA,Janssen Pw,Ten Berg JM.Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting[J].Curr Opin Cardiol,2015,30(4):319-324.
[13]Badheka AO,Patel NJ,Grover P,et al.Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes:a 5-year United States experience(2005-2009)[J].Circulation,2014,130(16):1392-1406.
[14]Peterson ED,Dai D,De Long ER,et al.Contemporary mortality risk prediction for percutaneous coronary intervention:results from588 398 procedures in the National Cardiovascular Data Registry[J].J Am Coll Cardiol,2010,55(18):1923-1932.
[15]Jolly SS,Amlani S,Hamon M,et al.Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events:a systematic review and meta-analysis of randomized trials[J].Am Heart J,2009,157(1):132-140.
[16]Nikolsky E,Mehran R,Halkin A,et al.Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures:a meta-analysis[J].J Am Coll Cardiol,2004,44(6):1200-1209.
[17]Aggarwal A,Dai D,Rumsfeld JS,et al.Incidence and predictors of stroke associated with percutaneous coronary intervention[J].Am J Cardiol,2009,104(3):349-353.
[18]Dukkipati S,O'Neill WW,Harjai KJ,et al.Characteristics of cerebrovascular accidents after percutaneous coronary interventions[J].J Am Coll Cardiol,2004,43(7):1161-1167.
[19]金琴花,盖鲁粤,杨庭树,等.冠心病介入治疗1 501例并发症分析—单中心16年资料[J].中国介入心脏病学杂志,2004,12(6):326-329.
[20]Mueller C,Buerkle G,Buettner HJ,et al.Prevention of contrast media-associated nephropathy:randomized comparison of 2 hydration regimens in 1 620 patients undergoing coronary angioplasty[J].Arch Intern Med,2002,162(3):329-336.
[21]Solomon R,Werner C,Mann D,et al.Effects of saline,mannitol,and furosemide to prevent acute decreases in renal function induced by radiocontrast agents[J].N Engl J Med,1994,331(21):1416-1420.